SAN DIEGO, Oct. 8, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), will announce results of a Phase IIa clinical study for MN-221, a novel treatment for status asthmaticus, at 3:00 A.M., Eastern time, tomorrow October 9th. Following the announcement, MediciNova will host a conference call to discuss the results at 10:00 A.M. Eastern time.
